A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults.

Trial Profile

A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors VIVUS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Feb 2015 Results were presented, as per Vivus Inc. media release.
    • 06 Oct 2014 Results published online in Diabetes Care, according to a VIVUS media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top